Compare WRLD & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WRLD | IRWD |
|---|---|---|
| Founded | 1962 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 660.6M | 741.8M |
| IPO Year | 1994 | 2009 |
| Metric | WRLD | IRWD |
|---|---|---|
| Price | $138.62 | $3.25 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.94 |
| AVG Volume (30 Days) | 113.4K | ★ 2.6M |
| Earning Date | 04-27-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.15 |
| Revenue | ★ $564,841,465.00 | $298,276,000.00 |
| Revenue This Year | N/A | $57.95 |
| Revenue Next Year | $6.51 | $4.39 |
| P/E Ratio | ★ N/A | $22.90 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $104.99 | $0.55 |
| 52 Week High | $185.48 | $5.78 |
| Indicator | WRLD | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 55.39 | 35.02 |
| Support Level | $138.35 | $3.08 |
| Resistance Level | $140.69 | $3.53 |
| Average True Range (ATR) | 7.29 | 0.27 |
| MACD | -0.20 | -0.02 |
| Stochastic Oscillator | 53.93 | 21.05 |
World Acceptance Corp operates a small-loan consumer finance business. The company offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. It also offers income tax return preparation services to its loan customers and other individuals. The Company operates 1,024 branches in Alabama, Georgia, Idaho, Illinois, Indiana, Kentucky, Louisiana, Mississippi, Missouri, New Mexico, Oklahoma, South Carolina, Texas, Tennessee, Utah, and Wisconsin.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.